• Receipts from customers of $3.1M with positive net cashflow from operations of $0.1M
• Receipts from customers of $13.75M over last 12 months with positive net cash flow from operations of $1.43M
• Contracts awarded and/or extended in software-as-a-medical-device (SaMD) business by pharma customers, growing to ~$5.2M across 2 to 4-year terms

Resonance Health made significant progress in each of its 3-business focus areas; (i) Resonance Clinical, (ii) Software-as-a-Medical Device Image Analysis Services (SaMD), and (iii) TrialsWest. Resonance Clinical progressed the major-pharma $13.8M clinical trial services agreement and achieved a key milestone with the 29th patient being dosed. The TrialsWest business continues to expand, with the third site in Mandurah, WA, commencing operations. The SaMD business secured new service contracts and extensions with existing and new pharma customers, with contracted business now totaling ~$5.2M across 2-4 year terms. Including tendered work, total orders from clinical trial SaMD customers now potentially exceeds $8.5M. The company also continues to expand its central-read service offerings, with new services being contracted for upcoming clinical trials. Looking ahead, the company is exploring opportunities to commercialise its SaMD services in the Chinese Health-Check market. Resonance Health closed the quarter with $3.0M in cash and net cash of $0.2M.

The company is on track to meet its previously published guidance.

Resonance Health continues to execute its growth strategy across its 3 business segments. The group has experienced strong deal flow in recent months with robust prospective business sales leads as evidenced by record prospective forward orders in the SaMD business, strong growth in the TrialsWest clinic trial network, and solid execution of Resonance Clinical trial management contracts.